louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03227913: Evaluate the Link Between the Characteristics of Oral Physiology and the Formation of the Food Bolus During the Consumption of Dairy Products in Elderly People
Official title: Evaluate the Link Between the Characteristics of Oral Physiology and the Formation of the Food Bolus During the Consumption of Cheese Products in Elderly People
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Old Person
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2017-07-24
Enrollment: 80
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this study is to understand how dairy products enriched in minerals and proteins are broken down in the mouth. More specifically, investigators wish to evaluate the link between oral physiology (salivation and mastication) and formation of the food bolus during the consumption of enriched cheese, that is to say the way in which the food is broken down to be swallowed.

The study will take place at the INRA in Dijon during 2 one-hour sessions spread over 4 months. These two sessions will allow investigators to characterise the chewing behaviour of the subjects and their salivation, and the structure of the food bolus formed when eating the four products of the project.

For each of the four foods in each session:

* Two samples of saliva will be taken
* A video will be made of subjects eating one of the study products
* Subjects will chew the study foods and spit them out.


Eligibility criteria: Inclusion Criteria:

* Persons who have provided written consent
* Age ≥ 65 years old
* Persons living at home
* Persons who can travel independently

Exclusion Criteria:

* Adults under guardianship
* Persons without health insurance cover
* Persons in hospital
* Persons in institutions
* Persons whose Mini-Mental State Examination (MMSE) is \< 24
* Persons requiring enteral or parenteral nutrition
* Persons who in the previous 12 months received € 4500 for taking part in clinical trials, including the present study
* Persons in a period of exclusion of a previous study
* Food allergies (dairy products in particular)

Primary outcomes:
measure: Duration of chewing
timeFrame: Change from baseline at 4 months
measure: Frequency of chewing
timeFrame: Change from baseline at 4 months
measure: Rheology test
timeFrame: Change from baseline at 4 months
measure: calculation of insanity rate
timeFrame: Change from baseline at 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU Dijon Bourgogne
Study officials:
References:
Clinical trial NCT05577013: Kinesio Taping Versus Motor Relearning Program for Upper Limb
Official title: Combined Effects of Kinesiotaping and Motor Relearning Program on Upper Limb Motor Function After Stroke
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-10-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Stroke is described as rapidly developing clinical findings of localized or generalized impairment to cerebral function, with symptoms lasting 24 hours or longer, or leading to death, with no evident cause other than a vascular origin.

Stroke is a prevalent and debilitating illness that affects people all around the world. Stroke is the second or third largest cause of mortality in adults, as well as one of the primary causes of adult disability. Because the majority of stroke patients survive the initial illness, the long-term impacts on patients and their families have the greatest influence on health. Kinesiotaping is a revolutionary rehabilitation procedure. It's most typically used to treat sports injuries, however, it is progressively becoming effective in overcoming other abnormalities. Kinesio Tex tape brand is a flexible, thin, porous cotton fabric with an adhesive backing manufactured by Dr. Kenzo Kase. It provides cutaneous stimulation which facilitates or limit movement, aids in the reduction of edema, reduces pain and correct joint positions for easing muscle spasms.


Eligibility criteria: Inclusion Criteria:

* male and female of age 18 -60 years
* patients with post stroke duration of \>6 months
* both ischemic and hemorrhagic stroke
* modified ashworth scale of spasticity \< 3
* muscle power by manual muscle testing (MMT) ≥ 2
* no cognitive impairments by mini mental state examination (MMSE) \> 24
* cortical skin sensitivity preserved (two point discrimination, barognosis, fine and crude touch)

Exclusion Criteria:

* Participants failing to fall in this category would be excluded from the study.
* being hospitalized due to any reason other than stroke
* being subjected to treatment with botulinum toxin for \<1 year
* any other condition which affects the upper extremity
* contraindications for the application of Kinesio Taping: open wounds, skin infections such as cellulitis, allergies, skin xerosis

Primary outcomes:
measure: Fugel Meyer assessment scale for upper limb
timeFrame: week 8
measure: Functionality of Upper Limb
timeFrame: week 8
measure: Box and Block Test (BBT)
timeFrame: week 8
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Rehman Medical Institute
Study officials:
affiliation: Riphah International University
name: Ayesha Afridi, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00367913: Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
Official title: Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pulmonary Diseases
Keywords: pulmonary disease
Treatment of Opportunist Mycobacteria
Clarithromycin
Ciprofloxacin
M.vaccae
Pulmonary diseases caused by Opportunist Mycobacteria
Lead sponsor: British Thoracic Society
Sponsor class: OTHER
First posted: 2006-08-23
Enrollment: 400
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.


Eligibility criteria: Inclusion Criteria:

* Patients with pulmonary disease due to M.avium intracellulare, M.malmoense or M.xenopi. Aged 16 or over. With clinical and/or radiological evidence of active infection and producing sputum positive on culture on at least 2 occasions.

Exclusion Criteria:

* Pregnant women and women of childbearing age not taking adequate contraceptive precautions.

Patients who have sputum currently positive on culture for M.tuberculosis or M.bovis.

Patients who have AIDS or who are known to be HIV positive

Primary outcomes:
measure: Death rates
measure: Cure rates
measure: Relapse rates
measure: Unwanted effects of therapy
Secondary outcomes:
measure: Benefit or not of immunotherapy with M.vaccae
Other outcomes:
Locations:
city: Penarth
country: United Kingdom
facility: Llandough Hospital
state: Vale of Glamorgan
Study officials:
affiliation: British Thoracic Society, Research Committee
name: Ian Campbell, BSc MD FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00865813: Biopsy Incisional With Trepan in Periocular Lesions
Official title: Biopsy Incisional With Trepan in Periocular Lesions
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tumor
Keywords: Punch biopsy,
periocular
tumors.
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2009-03-19
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study was to identify accuracy rates of 2mm punch biopsy technique in diagnosing periocular malignancy.

Detailed description: In each case, the histology obtained at biopsy was compared with that identified at the time of tumor excision.

Eligibility criteria: Inclusion Criteria:

* All lesions were initially examined at the slitlamp, after which lesions with malignant characteristics such as texture, size or color alterations asociated with ulceration, prominent borders or elevated contours, irregular borders, telangiectasias or loss of eyelashes were included.

Exclusion Criteria:

* Lesions with not malignant characteristics

Primary outcomes:
measure: accuracy, positive predictive value, negative predictive value, sensitivity, specificity
timeFrame: In each case, the histology obtained at biopsy was compared with that identified at the time of tumor excision.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Sao Paulo - Hospital das Clinicas
name: Rachel C Carneiro
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04236713: Evaluation of Food Additive Contributions to Obesity - Feasibility Study 3
Official title: Evaluation of Food Additive Contributions to Obesity - Feasibility Study 3
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obesity
Lead sponsor: McMaster University
Sponsor class: OTHER
First posted: 2020-01-22
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effects of food additives on body weight in humans are largely unknown. This is a feasibility study in 10 obese adults who will be followed for 5 months. Eligible participants will be non-randomly assigned to 2 groups and will be taught how to limit the exposure to the studied food additives in their diet. Primary outcomes in this study are recruitment rate, retention rate and adherence to the proposed dietary intervention.


Eligibility criteria: Inclusion Criteria:

* BMI \>/=30 kg/m2
* willingness and ability to follow the proposed dietary interventions
* informed consent

Exclusion Criteria:

* previous or planned bariatric surgery in the next 1 year
* current or planned participation in any structured weight-loss programs in the next 6 months
* current or recent (within the last 6 months) use of weight-loss-inducing drugs or systemic steroids
* excessive alcohol consumption
* bipolar disorder or attention deficit hyperactivity disorder
* current use of anti-depressant or anti-psychotic medications
* eating disorder or any other active disorder that may lead to significant weight changes
* pregnancy or planned pregnancy in the next 1 year
* uncontrolled diabetes mellitus or diabetes requiring treatment with \>2 oral diabetes medications or with insulin

Primary outcomes:
measure: Recruitment rate
timeFrame: 0 months
measure: Retention rate in arm 1
timeFrame: 5 months
measure: Retention rate in arm 2
timeFrame: 5 months
measure: Adherence to the dietary intervention in arm 1
timeFrame: 2 to 5 months
measure: Adherence to the dietary intervention in arm 2
timeFrame: 2 to 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: McMaster University
state: Ontario
Study officials:
References:
Clinical trial NCT00569413: A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality
Official title: A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Hypoactive Sexual Desire Disorder
Erectile Dysfunction
Keywords: Sex
brain imaging
dopamine
sexual disorder
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
Collaborators: name: Ben-Gurion University of the Negev
First posted: 2007-12-07
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A group of healthy volunteers from the general public. A group of patients who suffer from sexual disorder from a primary care clinic.

Brief summary: The current study combines a molecular genetic perspective, self report and brain imaging to the study of human sexuality in control subjects and individuals from a sexual disorder clinic. The investigators hypothesize that the variability in components of the brain dopaminergic system expressed in the mesolimbic reward system can explain variability in human sexuality, especially in desire and pleasure associated with sex.

Detailed description: We intend to combine molecular genetics of the dopamine receptors (D2, D3 D4 and D5) and brain imaging using 11 C Raclopride in Positron Emission Tomography (PET). 11 C Raclopride is a ligand which binds to the dopamine receptor D2 and can measure dopamine release during pleasure or anticipatory reward associated with sex. The current proposal will measure changes in DRD2 receptor occupancy using 11 C Raclopride following explicit visual sexual desire cues in healthy control subjects and individuals who suffer from sexual dysfunction. This is in order to determine how individual genotypes modulate dopamine release in vivo in the human brain.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers and patients
* Age 21-65
* Male or female

Exclusion Criteria:

* Psychiatric diagnosis/psychosis
* Neurological damage associated with loss of consciousness
* Infectious disease HIV
* Herpes
* Syphilis
* Hyperactivity treated with ritalin
* Pregnant women
* Under age

Primary outcomes:
measure: Brain Imaging data of DRD2 receptor occupancy during watching a sex videotape and neutral videotape
timeFrame: 2 Brain imaging sessions a week apart
Secondary outcomes:
measure: Questionnaire ratings of human sexuality, pleasure, and anticipatory reward
timeFrame: Taken during brain scans
Other outcomes:
Locations:
Study officials:
affiliation: Hadasah Medical Organization, Jerusalem Israel
name: Aviv M Weinstein, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00175513: V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis
Official title: V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Psychosis
Keywords: Psychosis
early psychosis
first episode psychosis
schizophrenia
schizoaffective
schizophreniform
bipolar disorder
valtrex
valacyclovir.
Lead sponsor: University of British Columbia
Sponsor class: OTHER
Collaborators: name: Stanley Medical Research Institute
First posted: 2005-09-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an 18 week (2 weeks run-in, 16 weeks double blind) trial, to determine if an antiviral drug, valacyclovir (Valtrex) is helpful in treating the symptoms of psychosis, a form of a mental disorder.

Detailed description: There is evidence that some of the symptoms of psychosis may be related to past infection with common viruses.

Researchers are looking to recruit a total of 100 subjects with evidence in the past, of exposure to at least 1 of 3 viruses. The viruses include herpes type 1 (HSV-1, which causes cold sores of the lip and has affected about 6/10 people in Vancouver), herpes type 2 (HSV-2 which causes genital sores, and has affected less than 1/10 people in Vancouver) and cytomegalovirus (CMV, which causes few symptoms but has affected 8/10 people in Vancouver). People who have been infected with these viruses in the past develop antibodies in the blood. The antibodies can be measured in blood, and are a test of whether or not there was infection in the past, and possibly affecting the symptoms of psychosis.

Eligibility criteria: Inclusion Criteria:

* Subjects antipsychotic, mood stabilizing and antidepressant drug treatment must have been stable for at least 3 months, and there is no plan to change the drug treatment during the 4-month phase of the study.
* Subjects must be seropositive for HSV-1, HSV-2 and/or CMV.
* Subjects must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.
* Subjects must be able to provide written informed consent.

Exclusion Criteria:

* Females of childbearing age will agree not to become pregnant and will agree to use a medically acceptable method of birth control.
* Inability to participate in cognitive testing due to severe persistent psychosis or other condition.
* Mental handicap.
* Subjects with known hypersensitivity or allergy to valacyclovir or acyclovir.
* Patient taking nontopical antiviral medications with anti-herpes activity on a regular basis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Victoria
country: Canada
facility: Eric Martin Pavilion
state: British Columbia
city: White Rock
country: Canada
facility: Peace Arch Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: William Honer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03316313: Hepatitis C Screening in the Primary Care Setting
Official title: Prospective Cohort Study: Hepatitis C Screening in the Primary Care Setting
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C
Keywords: Public Health
Patient Education as Topic
Hepatitis C
Lead sponsor: New York Institute of Technology
Sponsor class: OTHER
First posted: 2017-10-20
Enrollment: 503
Sex: ALL
Minimum age (years): 50
Maximum age (years): 71
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Screening was performed at two locations with differing socioeconomic data per census reports.

Brief summary: The purpose of this study is to determine whether patient education improves Hepatitis C screening in the primary care setting.

Detailed description: Hepatitis C is a chronic, asymptomatic infection that progresses to liver cirrhosis and cancer in the later stages if left untreated. The Centers for Disease Control (CDC) recommends a one-time screening for high risk birth cohort between the years 1945-1965. Prior studies have evaluated methods to improve screening for hepatitis c with focus on increasing awareness in health professionals. Targets included nursing staff and electronic medical records. This study targets providing patients with education resources to see if screening rates improve.

Eligibility criteria: Inclusion Criteria:

* All patients born between the years 1945 and 1965.

Exclusion Criteria:

* Patients who had already received a prior screening test for Hepatitis C before the office visit.

Primary outcomes:
measure: Number of Patients Screened for Hepatitis C
timeFrame: June 2016 to October 2016.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00107913: Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Official title: Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Autoimmune Thrombocytopenic Purpura
Keywords: Immune Thrombocytopenic Purpura
Lead sponsor: Hematology and Oncology Specialists
Sponsor class: OTHER
First posted: 2005-04-12
Enrollment: 10
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Detailed description: Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.

Eligibility criteria: Inclusion Criteria:

* Thrombocytopenia with bone marrow findings showing normal or increased numbers of megakaryocytes.
* Failure to respond to initial treatment with steroids, IV immune globulin, splenectomy and post splenectomy steroids.
* Platelet count of 30,000 or less.
* Performance status score of 2 or less.
* Adequate organ function: \*bilirubin\< 2; \*AST \< 3 times normal; \*creatinine \< 2.
* No prior treatment with anthracycline or chemically related drugs.

Exclusion Criteria:

* Pregnant or lactating women.
* Presence of a malignancy other than basal cell carcinoma of the skin.

Primary outcomes:
measure: the primary outcome would be a platelet response, with a return of platelet count to normal
Secondary outcomes:
Other outcomes:
Locations:
city: Metairie
country: United States
facility: Hematology and Oncology Specialists
state: Louisiana
Study officials:
affiliation: Hematology and Oncology Specialists
name: Thomas M Cosgriff, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03091413: Correlation Between Pi Max and Diaphragm Maximum Inspiratory Excursion Detected With Ultrasound During Weaning
Official title: Correlation Between Pi Max and Diaphragm Maximum Inspiratory Excursion Detected With Ultrasound During Weaning
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Weaning
Diaphragm Ultrasound
Maximum Inspiratory Pressure
Lead sponsor: Corporacion Parc Tauli
Sponsor class: OTHER
First posted: 2017-03-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All ICU patients of Hospital de Sabadell who meet criteria for weaning will be included in the study.

Brief summary: This study evaluates the correlation between maximum inspiratory pressure (Pi max) and the diaphragm maximum inspiratory excursion measured with ultrasound during the weaning from invasive mechanical ventilation.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years.
* Invasive Mechanical Ventilation \> 24 hours.
* Readiness for weaning (following clinician decision made according to recent guidelines).

Exclusion Criteria:

* Impossibility to perform an echography.

Primary outcomes:
measure: Pimax and diaphragm inspiratory excursion
timeFrame: 4 months
Secondary outcomes:
measure: Predicting value of diaphragm excursion
timeFrame: 4 months
measure: Combination index prediction for weaning
timeFrame: 4 months
Other outcomes:
Locations:
city: Sabadell
country: Spain
facility: Candelaria De Haro
state: Barcelona
Study officials:
References: